Danaher Q2: Inventory Overhang, But Low Expectations Limit Downside
Summary: Danaher Corporation stock saw a high single-digit percentage increase from April to mid-June, but
Summary: Danaher Corporation stock saw a high single-digit percentage increase from April to mid-June, but
Summary: The valuation is historically high, while sales are falling year-on-year. Danaher is issuing worse
Summary: Mar Vista initiated an investment in Danaher due to durable competitive advantages, compounding intrinsic
Summary: Danaher Corporation’s core sales growth rate is expected to turn positive as 2024 progresses.
Summary: Danaher Corporation stock has surged by 16% since our “Strong Buy” rating in June
Summary: Danaher Corporation, a healthcare/biotech/life sciences supplier, has shown resilience and strength in its core
Summary: Danaher Corporation is a leading player in the life science industry, with strong financial
Summary: Danaher’s annual results show a decrease in sales and EBIT due to the boost
Summary: Despite recent challenges, Danaher remains resilient and strategically positioned for long-term success. Danaher’s 4Q23
Summary: Danaher has undergone a radical transformation from a real estate trust to a leader